达雷妥尤单抗联合硼替佐米、沙利度胺和地塞米松治疗新诊断多发性骨髓瘤:CASSIOPEIA研究微小残留病结果
CASSIOPEIA研究在适合移植的新诊断多发性骨髓瘤患者中比较D-VTd与VTd诱导/巩固及达雷妥尤单抗维持与观察,中位随访80.1个月显示D-VTd提高微小残留病阴性率并带来无进展生存获益,达雷妥尤单抗维持进一步提高微小残留病阴性率并改善无进展生存。
要点
- D-VTd较VTd提高诱导后和巩固后微小残留病阴性率(10⁻⁵)。
- 达雷妥尤单抗维持较观察提高微小残留病阴性率(10⁻⁵和10⁻⁶)。
- D-VTd后达雷妥尤单抗维持产生最高且持久的微小残留病阴性率。
核心结论
- 以达雷妥尤单抗为基础的诱导/巩固后接达雷妥尤单抗维持治疗可获得最深、最持久的微小残留病阴性,并带来更优的无进展生存。
研究设计与样本
- CASSIOPEIA研究为随机对照试验,患者按1:1随机分配至达雷妥尤单抗联合硼替佐米、沙利度胺和地塞米松(D-VTd)组或VTd诱导/巩固组。
- 仍在研究中的患者再次随机分配至达雷妥尤单抗维持治疗或观察,维持治疗时长≤2年。
- 微小残留病状态在各研究阶段的预设时间点评估,本次报告中位随访80.1个月。
主要发现
- 诱导后总体微小残留病阴性率(10⁻⁵):D-VTd组34.6% vs VTd组23.1%。
- 巩固后总体微小残留病阴性率(10⁻⁵):D-VTd组63.7% vs VTd组43.7%。
- D-VTd较VTd单用提供无进展生存获益,与诱导后微小残留病状态无关。
- 达雷妥尤单抗维持较观察提高总体微小残留病阴性率(10⁻⁵):D-VTd/达雷妥尤单抗组77.3% vs D-VTd/观察组70.7%;VTd/达雷妥尤单抗组70.9% vs VTd/观察组51.2%。
- 达雷妥尤单抗维持较观察提高总体微小残留病阴性率(10⁻⁶):D-VTd/达雷妥尤单抗组60.7% vs D-VTd/观察组52.0%;VTd/达雷妥尤单抗组48.4% vs VTd/观察组30.7%。
关键数值与推荐
- 微小残留病阴性率在10⁻⁵和10⁻⁶水平评估,数值如原文所列。
- 达雷妥尤单抗维持较观察提供无进展生存获益,与诱导/巩固治疗及巩固后微小残留病状态无关。
- D-VTd后接达雷妥尤单抗维持持续产生最高的里程碑、累积和持续微小残留病阴性率(10⁻⁵和10⁻⁶),并转化为更优的长期无进展生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance vs observation in transplant-eligible, newly diagnosed multiple myeloma. Here, we present long-term MRD status and PFS outcomes after a median follow-up of 80.1 months. Patients were randomly assigned (1:1) to daratumumab plus VTd (D-VTd) or VTd induction/consolidation; patients remaining on study were rerandomized to daratumumab maintenance or observation for ≤2 years. MRD status was assessed at predefined time points during each study phase. D-VTd improved overall MRD-negativity rates (10-5) after induction (34.6% vs 23.1%) and consolidation (63.7% vs 43.7%) and provided PFS benefit, regardless of postinduction MRD status, vs VTd alone. Daratumumab maintenance improved overall MRD-negativity rates over observation, regardless of induction/consolidation treatment (D-VTd/daratumumab vs D-VTd/observation, 10-5 [77.3% vs 70.7%] and 10-6 [60.7% vs 52.0%]; VTd/daratumumab vs VTd/observation, 10-5 [70.9% vs 51.2%] and 10-6 [48.4% vs 30.7%]) and improved MRD-negativity rates, regardless of risk status, as defined by cytogenetic abnormalities or the revised International Staging System score. Furthermore, daratumumab maintenance provided PFS benefit vs observation, regardless of induction/consolidation treatment and postconsolidation MRD status. D-VTd followed by daratumumab maintenance consistently produced the highest landmark, cumulative, and sustained MRD-negativity rates (10-5 and 10-6), translating to superior long-term PFS outcomes. These results demonstrate that daratumumab-based induction/consolidation followed by daratumumab maintenance resulted in the deepest and most durable MRD negativity, leading to superior PFS outcomes. This trial was registered at www.clinicaltrials.gov as #NCT02541383.
引用
- Corre J, Vincent L, Moreau P, et al. Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results. Blood. 2025. PMID: 40127397. doi:10.1182/blood.2024027620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。